Imatinib Normon

Imatinib, the active ingredient in Imatinib Normon, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Normon as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib is a tyrosine kinase inhibitor used in hematologic malignancies and selected solid tumours. - Chronic myeloid leukemia: controls disease by targeting BCR‑ABL‑positive cells, leading to cytogenetic and molecular remission. - Acute lymphoblastic leukemia: used in Ph‑positive ALL to achieve remission in combination regimens. - Gastrointestinal stromal tumor: inhibits c‑KIT driven tumours, improving progression‑free survival.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often of the ankles. - Fatigue: generalized tiredness. - Muscle cramps: intermittent painful contractions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: congestive heart failure or reduced ejection fraction. - Severe neutropenia: marked decrease in neutrophil count increasing infection risk.

When prescribing Imatinib, clinicians should consider several safety and handling precautions. - Monitor liver function: perform baseline and periodic LFTs. - Assess cardiac status: evaluate ejection fraction before and during therapy. - Check blood counts: regular CBC to detect cytopenias. - Evaluate drug interactions: review concomitant CYP3A4 inhibitors or inducers. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise imatinib levels, risking toxicity. - Strong CYP3A4 inducers (e.g., rifampicin): may lower imatinib exposure, reducing efficacy.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect absorption, monitor therapeutic response. - Antacids containing aluminum or magnesium: can reduce bioavailability, separate dosing by at least 2 hours. - Concomitant anticoagulants (e.g., warfarin): increased bleeding risk, monitor INR.